alexa Safety Concerns Related To Global Biosimilars Drug Development | 22460
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference and Exhibition on Biowaivers, Biologics & Biosimilars

Nigel Rulewski
ScientificTracks Abstracts: J Bioanal Biomed
DOI: 10.4172/1948-593X.S1.013
Abstract
This session will focus on safety-related aspects of biosimilars development; noting that the global biosimilars market includes monoclonal antibody biosimilars, insulins, interferons, erythropoetins, filgrastim, somatropin and follicle stimulating hormone. As of April 2014, biosimilars have been on the market for eight years and around 300 million patient days have been generated. The session notes that while European and Canadian regulatory authorities still hold a global leadership role in biosimilar drug development, with no biosimilars approved to date in the United States, these products are widely used in the EU, Canada, Japan and Australia, and have the potential for price discounts of 10 to 50 percent of reference product prices. The author notes that although an untoward safety event occurred in the 1990s, early in the development of biologics, that was due to a change in formulation of erythropoietin, since then, biosimilar drug development has proven safe over a significant time span. Nonetheless, this session cautions that with the existing diversity of regulatory sophistication between markets, there is the possibility for a problematic safety signal to result from five scenarios: ? Marketing approvals based on small clinical trials ? outsourcing of manufacturing ? pressure for speed to market ? trials in emerging markets ? lack of specific regulatory guidance and biosimilar approvals in the US. All five scenarios will be discussed in greater detail during the session.
Biography
Nigel Rulewski holds an MB and BS from St. Bartholomew?s Medical School, University of London, a Diploma in Child Health from the Royal College of Physicians and a Diploma from the Royal College of Obstetricians and Gynecologists. He has over 25 years of experience in drug development and regulatory affairs in both large and small pharmaceutical companies and has worked in venture capital and pharmaceutical business development. He currently serves as Head of Quintiles Global Biosimilar Unit.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7